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Background: COPD patients with chronic bronchitis include a subgroup with persistent sputum
production on most or every day. We hypothesized that COPD patients with persistent sputum
production have a different profile of airway inflammation, and more severe clinical character-
istics.
Objective: To compare the airway inflammation profile and clinical characteristics of COPD
persistent and non-persistent sputum producers.
Methods: COPD persistent sputum producers (n Z 26) and non-persistent sputum producers
(n Z 26) underwent sputum induction and pulmonary function tests. Exacerbation history
was recorded; the St. George’s Respiratory Questionnaire, Modified Medical Research Council
Dyspnoea scale and COPD Assessment Tool were completed. 33 COPD patients provided sputum
for bacteriology.
Results: Persistent sputum producers had lower post-bronchodilator FEV1% predicted
(pZ 0.01), diffusion capacity (pZ 0.04), 6 min walk test distance (pZ 0.05), and higher clos-
ing volume (p Z 0.01), BODE index (pZ 0.01), rate of bacterial colonization (pZ 0.004) and
exacerbations (p Z 0.03) compared to non-persistent sputum producers. The mean SGRQ and
CAT scores were higher in persistent sputum producers (p Z 0.01 and 0.03 respectively).
Sputum neutrophil and eosinophil total cell counts were higher in persistent sputum producers
(pZ 0.02 and 0.05 respectively). Sputum levels of eotaxin (pZ 0.02), MCP-1 (pZ 0.02), TNF-
a (p Z 0.03) and IL-6 (p Z 0.05) were higher in persistent sputum producers.9@hotmail.com, shrutikhurana799@gmail.com (S. Khurana), aravi@meu.org.uk (A. Ravi), justyna.
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1762 S. Khurana et al.Conclusion: COPD persistent sputum producers have more severe clinical characteristics and
increased concentrations of some inflammatory mediators in the airways.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
The hallmark features of COPD are poorly reversible airflow
obstruction and persistent pulmonary inflammation [1]. It is
recognized that disease phenotypes exist, comprising sub-
groups of patients with distinct clinical or pathological
characteristics associated with different prognosis or
response to treatment [2].
Chronic bronchitis is defined as a productive cough for
3 months for 2 consecutive years. There is evidence that
chronic bronchitis is associated with more severe airflow
obstruction and breathlessness [3,4], an excessive decline
in FEV1 [5], and higher exacerbation [6e8] and mortality
rates [9e11]. However, recent large observational studies
have not consistently reproduced these findings; The COPD
Gene Cohort study showed that chronic bronchitis is asso-
ciated with more exacerbations but not with other clinical
characteristics [12], while the ECLIPSE study only showed
that COPD patients with chronic bronchitis had worse
general health status [13]. These different outcomes may
be due to the broad range of symptom severity covered by
the definition of chronic bronchitis; Some COPD patients
fall into the category of ‘chronic bronchitis’ due to a pro-
ductive cough for a few months, while others have a
persistent productive cough for most or every day of the
year. The inclusion of patients with mild chronic bronchitis
in clinical studies, as opposed to those with severe and
persistent sputum production, is likely to reduce the
chance of observing positive findings.
Mucins are glycosylated proteins secreted by the airway
epithelia that form gels that are key components of mucus
in the lungs [14]. MUC5AC and MUC5B are the major mucin
subtypes expressed in the lungs, with epithelial MUC5AC
expression upregulated in COPD patients [15,16]. A number
of cytokines upregulate mucin expression [17], and may
cause mucus hypersecretion in COPD. Previous studies
evaluating cytokine levels in COPD patients with chronic
bronchitis have used healthy control groups [18e20].
However, the optimal study design to investigate cytokines
associated with the presence of chronic bronchitis in COPD
is to compare COPD patients with and without chronic
bronchitis. This approach has been used for airway in-
flammatory cells; eosinophil numbers were increased in
induced sputum and decreased in the bronchial submucosa
of COPD patients with chronic bronchitis [21], suggesting
that eosinophil chemotaxis is altered.
The primary aim of this study was to investigate clinical
characteristics and sputum inflammatory biomarkers in
COPD patients with chronic bronchitis. The novel aspects
were to focus on COPD patients with symptoms of persis-
tent sputum production, in order to maximize the chance of
finding differences between groups, and to use a control
group of COPD patients without chronic bronchitis, in
contrast to previous studies of sputum cytokines that haveused healthy controls [19,20,22]. We processed sputum
using a ‘two-step’ procedure [23], using phosphate buff-
ered saline (PBS) processing first to obtain supernatant
followed by dithiothreitol (DTT) to obtain cells. This avoids
any effect of DTT on cytokine analysis from sputum super-
natant. A secondary aim of this study was to compare re-
sults from induced and spontaneous sputum samples from
persistent sputum producers, in order to determine which
type of sample provides better sample quality and repro-
ducibility in this patient group.
Methods
Subjects
COPD patients, diagnosed according to current criteria
[24], were recruited from the clinical research database of
the Medicines Evaluation Unit, University Hospital of South
Manchester Foundation Trust. Patients were excluded if
they had experienced a respiratory tract infection or
exacerbation of COPD in the preceeding 6 weeks. Fifty two
COPD patients participated in the main study where clinical
characteristics and sputum cytokine levels were assessed.
Thirty three COPD patients, including 22 from the main
study, participated in a follow-on study where bacterial
colonization in sputum was assessed. All patients provided
written informed consent, and the local ethics committee
approved the study.
Patients were identified as persistent sputum producers
using the validated American Thoracic Society question-
naire [25]; Patients bringing up phlegm at least twice a day
for four or more days of the week were categorized as
persistent sputum producers. Non-persistent sputum pro-
ducers were defined as patients who did not produce
phlegm except during an exacerbation.
Study design
Measurements of pulmonary function including spirometry,
lung volumes, gas transfer (KCO), single breath nitrogen
washout were performed, and six minute walk test (6 MWT)
and sputum induction. Full details of the methods are in the
online data supplement. Exacerbation history using patient
recall verified by primary care records in the previous 12
months was recorded. An exacerbation was defined as an
acute change in dyspnoea, cough or sputum requiring
treatment with antibiotics, oral corticosteroids or both. St.
George’s Respiratory Questionnaire (SGRQ), Modified Med-
ical Research Council dyspnoea scale (MMRC) and COPD
Assessment Tool (CAT) were completed, and the BODE
index calculated [26]. High resolution CT scan (HRCT) (GE
Medical Systems, Light Speed L52002) had been performed
on 26 patients in the previous year; we did not specifically
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bronchiectasis was based on radiologist assessment. To
assess sputum repeatability, 12 patients from the persistent
sputum producer group provided a repeat sputum sample
after 2 months.
We conducted a further study one year after this main
study, where sputum samples were analysed for bacterial
colonization in persistent sputum producers compared to
non-persistent sputum producers.
Sputum collection and processing
Patients were asked to blow their nose and rinse their
mouth with water prior to providing a spontaneous sputum
sample. Spontaneous sputum was collected over a
maximum of 30 s. Sputum induction was performed
approximately 2 h later using normal saline as previously
described [27].
Sputum plugs were selected to separate sputum from
saliva in both spontaneous and induced samples, and then
processed using a 2 step procedure [23], using PBS pro-
cessing first to obtain supernatant followed by DTT to
obtain cells. Full details are in the online data supplement.
Supernatant analysis
Cytokines and chemokine levels in sputum supernatants
were assayed using a Meso Scale Discovery (MSD, Gai-
thersburgeUSA) multiplex platform at GSK (Stevenage, UK).
The limits of detection (LOD) are stated in the online data
supplement.
Quantitative sputum culture
Sputum culture was conducted and potential pathogenic
species identified using standardized methods [28]. Full
details of the method are in the online data supplement.
Statistical analyses
The power of the study was 80%; at least 16 subjects per
group were required to detect a neutrophil percentage
difference of 15%, based on a within subject standard de-
viation of 14.4% [29]. Unpaired t-tests were performed for
parametric data (spirometry, body plethysmography, gas
transfer, nitrogen washout, SGRQ and CAT scores and non-
eosinophil related sputum data). ManneWhitney U tests
were performed on non-parametric data (MMRC, exacer-
bation history and sputum eosinophil data). Ordinal
regression was performed to determine whether sputum
producer status was associated with FEV1% predicted and
SGRQ total score (independent of age, gender and current
smoking status).
Sputum cytokine data were non-parametric, and are
presented as medians and analysed using ManneWhitney U
tests. Inflammatory mediators could be normalized
following logarithmic transformation and were analysed
using unpaired t-tests. Sputum cytokines levels registering
below the LOD were assigned a value of ‘zero’ for the
purpose of statistical analysis. The statistical significance of
differences observed in differential cell count dataobtained from unmatched spontaneous and induced sputum
samples (persistent sputum producers) was assessed using
unpaired t-tests. Fisher’s exact test was used to assess the
statistical significance of differences in bacterial coloniza-
tion rates between groups. Differences in sputum cell
counts and protein measurements between individuals with
post-bronchodilator FEV1>50% predicted (GOLD I þ II) and
FEV1<50% (GOLD III) predicted were determined using
either unpaired t-tests or ManneWhitney U tests. Univari-
ate correlations of sputum cell counts and protein mea-
surements were performed using the Spearman Rank test;
this analysis involved multiple simultaneous comparisons
therefore a p value of <0.01 was considered as being sig-
nificant. Repeatability was assessed by paired t-tests, intra-
subject standard deviation (SD) and intraclass correlation
coefficient (Ri). Statistical analyses were performed using
PRISM version 5 (GraphPad Software, San Diego, California,
USA) or SPSS software (IBM Corp. Released 2011. IBM SPSS
Statistics for Windows, Version 20.0. Armonk, NY: IBM
Corp.)
Results
Clinical characteristics
Table 1 shows that the main study consisted of 26 persistent
sputum producers and 26 non-producers, with the majority
of patients being GOLD II. No patients had FEV1 reversibility
>12%. Some KCO% predicted values were >100% in patients
with higher BMI (this has been previously reported) [30,31].
Univariate analysis showed that persistent sputum pro-
ducers had significantly lower FEV1% predicted (p Z 0.01)
and KCO% predicted (p Z 0.04), and a higher closing vol-
ume (p Z 0.01) compared to sputum non-producers.
Persistent sputum producers also had numerically higher
RV, but the difference between groups did not reach sta-
tistical significance (p Z 0.13). Persistent sputum pro-
ducers had a reduced 6 min walk test distance (p Z 0.05).
Persistent sputum producers had significantly higher SGRQ
score (pZ 0.01), CAT score (pZ 0.03) and a trend towards
significance for MMRC score (p Z 0.07). The number of
exacerbations in the previous year was higher (p Z 0.03),
and the BODE index score was worse in persistent sputum
producers (p Z 0.01).
Ordinal regression showed that persistent sputum pro-
duction was a significant predictor of lower FEV1% pre-
dicted (pZ 0.001) and higher SGRQ total score (pZ 0.01),
independent of age, gender and current smoking status; see
e-Table 1 in online data supplement. High resolution CT
scan on 16 persistent sputum producers and 10 non-
producers identified only 2 persistent sputum producers
with minor secondary bronchiectasis.
Sputum cell counts
All the persistent sputum producers provided a spontaneous
and an induced sputum sample, although induced samples
from 2 patients were unsuitable for analysis due to a high
proportion of non-viable cells. Induced sputum was ob-
tained in 22/26 non-producers. The total cell count (TCC) in
induced samples was increased in persistent sputum
Table 1 Demographic and clinical details.
Persistent sputum
producer (n Z 26)
Non-persistent sputum
producer (n Z 26)
p value
Age (Years) 65.7 (6.91) 66.8 (6.46) 0.56
Female gender (n) 14 12 0.58
Smoking history (Pack years)# 35.30 (12.5e86) 32.00 (18.50e122.2) 0.49
Current smokers (n) 15 12 0.41
BMI (kg/m2) 28.50 (4.30) 27.56 (5.33) 0.26
GOLD I (n) 1 4
GOLD II (n) 16 17
GOLD III (n) 9 5
GOLD IV (n) 0 0
SABA (n) 23 24 0.64
SAMA (n) 2 3 0.64
LABA (n) 17 20 0.36
LAMA (n) 12 11 0.78
ICS (n) 17 20 0.36
Post bronchodilator FEV1
(% predicted)
54.5 (13.09) 65.1 (16.25) 0.01*
Post bronchodilator
FEV1/FVC (% predicted)
46.9 (6.61) 50.1 (4.43) 0.12
TLC (% Predicted) 105.7 (16.75) 103.2 (22.17) 0.55
RV (L) 3.3 (1.13) 2.6 (0.88) 0.13
IC (L) 2.0 (0.66) 2.2 (0.18) 0.26
IC/TLC 0.3 (0.09) 0.4 (0.09) 0.18
KCO (% Predicted) 78.2 (20.26) 93.5 (21.73) 0.04*
Closing volume (L) 1.0 (0.41) 0.7 (0.36) 0.01*
N2 D/L 6.5 (2.54) 7.1 (2.82) 0.77
6 MWT (m) 350 (85.40) 395.4 (73.54) 0.05*
BODE Index 2.4 (1.77) 1.3 (1.44) 0.01*
SGRQ score (Total score/100) 44.2 (20.34) 29.4 (17.21) 0.01*
SGRQ symptom score (Score/100) 52.9 (20.42) 31.7 (22.89) 0.002*
SGRQ impact score (Score/100) 56.3 (27.70) 43.5 (26.49) 0.01*
SGRQ activity score (Score/100) 34.5 (19.66) 21 (15.54) 0.07*
MMRC score (0e4)# 1.5 (1.0e4.0) 1 (0e3.0) 0.07
CAT score (Score/40) 20 (07.95) 14 (06.53) 0.03*
Exacerbations in last 12 months 1 (0e4.0) 0 (0e2.0) 0.03*
Data presented as mean ( standard deviation). # Data represented as median (range). For continuous data, the statistical significance
of differences observed between groups was determined using t tests. For categorical data, the statistical significance of differences
observed between groups was determined using the c2 test. Abbreviations e SABA: short acting b agonist; SAMA: short acting muscarinic
antagonist; LABA: long acting b agonist; LAMA: long acting muscarinic antagonist: ICS: inhaled corticosteroid; TLC: total lung capacity;
RV: residual volume; IC: inspiratory capacity; KCO: diffusion capacity; N2 D/L: slope of nitrogen washout curve; 6 MWT (m): six minute
walk test distance (in meters); SGRQ: St George’s Respiratory Questionnaire; MMRC: Modified Medical Research Council Dyspnoea score;
CAT: COPD assessment tool; BMI: body mass index; BODE: BMI/obstruction (FEV1% predicted)/Dyspnoea (MMRC score)/Exercise capacity
(6 MWT distance), *shows p value  0.05.
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cance (pZ 0.09), while the total neutrophil and eosinophil
counts were significantly increased in persistent sputum
producers; see Table 2. The cell differential percentage
counts were similar between groups, and the proportion of
patients with eosinophils >3% were similar (p Z 0.86).
The mean viability of all spontaneous sputum samples
from persistent sputum producers was reduced and the
squamous cell percentage was higher compared to induced
samples; see Table 3. There were no other differences
between spontaneous and induced samples. Further anal-
ysis of paired spontaneous and induced samples is shown in
the online supplement (e-Table 2).Supernatant cytokines
Persistent sputum producers had significantly higher levels
of eotaxin (pZ 0.02), MCP-1 (pZ 0.02), TNF-a (pZ 0.03)
and IL-6 (p Z 0.05), with a trend towards significance for
MCP-4 and IL-13 (both p Z 0.06) compared to non-
persistent sputum producers (Fig. 1). There were
increased GM-CSF levels in persistent sputum producers
(p Z 0.01), but the levels were low with many samples
below the limit of detection (see e-Fig. 1 in the online data
supplement). There were no differences (p > 0.05) be-
tween groups for other inflammatory mediators; see e-
Table 3 in the online data supplement. There were no
Table 2 Induced sputum cell counts in COPD persistent sputum producers & non-producers.
Persistent sputum
producer (n Z 24)
Non persistent sputum
producer (n Z 22)
p value
Total cell count (106) 3.5 (3.49) 2.2 (3.67) 0.09
Leucocyte viability % 74 (26.13) 71.1 (23.22) 0.66
Squamous cell % 1.6 (2.24) 1.1 (2.45) 0.34
Neutrophil % 73 (20.75) 60.9 (34.54) 0.61
Macrophage % 17.5 (13.09) 14.4 (14.83) 0.11
Eosinophil % 1.6 (0.50e3.69) 1 (0.19e2.31) 0.20
Neutrophil cell count (106) 2.9 (3.32) 1.6 (3.98) 0.02*
Macrophage cell count (106) 0.7 (0.42) 0.3 (0.55) 0.24
Eosinophil cell count (106) 0.1 (0.03e0.11) 0.02 (0.01e0.06) 0.05*
n Z 24 in persistent sputum producer group as 2 patients gave induced sputum samples that were non-viable; n Z 22 in the non-
persistent sputum producer group as 4 patients did not produce sputum on induction. Data represented as mean (SD). Eosinophil %
and cell count expressed as median (range). Abbreviation e TCC: total cell count.
* Shows p value 0.05.
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(data not shown).
We analysed these data according to GOLD stage
determined by the degree of airflow obstruction; there
were no differences between patients with mild to mod-
erate airflow obstruction (GOLD I/II) versus severe airflow
obstruction (GOLD III) for supernatant cytokines; see e-
Table 4 in online data supplement. However, sputum total
cell counts, neutrophil and eosinophil cell counts and
neutrophil percentage were increased in GOLD stage III
patients.
Sputum culture
The demographics of patients who provided samples for
sputum culture are shown in Table 4. Bacteria were
detected at a significantly higher rate (p Z 0.004) in
persistent sputum producers (12 out of 20 patients; 60%)
compared to non-persistent sputum producers (1 out of 13;
7.7%). The most frequent micro-organisms isolated in the
persistent producer group were Haemophilus influenzae
[n Z 7; mean count: 1.96 (SD 2.36)  108 CFU/g] and
Streptococcus pneumoniae [n Z 3; mean count: 4.39 (SDTable 3 Induced and spontaneous sputum cell counts in COPD
Induced sample (n Z 24)
Total cell count (106) 3.5 (3.49)
Leucocyte viability % 74 (26.13)
Squamous cell % 1.6 (2.24)
Neutrophil % 73 (20.75)
Macrophage % 17.5 (13.09)
Eosinophil % 1.6 (0.50e3.69)
Neutrophil cell count (106) 2.9 (3.32)
Macrophage cell count (106) 0.7 (0.42)
Eosinophil cell count (106) 0.1 (0.03e0.11)
n Z 24 in persistent sputum producer (induced) group as 2 patients
persistent sputum producer (spontaneous) group as 8 slides in this g
(>10%); Data represented as mean (SD). Eosinophil % and cell count e
* Shows p value 0.05.4.91)  108 CFU/g]. One sputum sample was positive for
bacteria in non-persistent sputum-producers (Haemophilus
influenzae). The individual sputum bacterial cell counts are
shown in e-Table 5 in the online data supplement.
Sputum repeatability
The repeatability of samples from 12 persistent sputum
producers is shown in Table 5. The mean values of repeated
samples were not different (p > 0.05) for induced or
spontaneous sputum cell counts. There was much better
agreement between visits for induced sputum, with Ri
values indicating moderate to good agreement, compared
to spontaneous sputum where Ri values were generally 0.3
or less, indicating slight or poor agreement. The neutrophil
percentage within subject SD for induced samples was 13%.Discussion
We have demonstrated that COPD patients with persistent
sputum production have worse airflow obstruction, reduced
exercise capacity, greater symptoms and morepersistent sputum producers.
Spontaneous sample (n Z 18) p value
4.5 (10.2) 0.65
51.2 (14.5) <0.0001*
3.7 (4.9) 0.06
68.1 (18.1) 0.31
23.7 (15.8) 0.25
1.3 (0e31) 0.42
3.6 (9.4) 0.24
1.8 (5.2) 0.76
0.02 (0e0.5) 0.29
gave induced sputum samples that were non-viable; n Z 18 in
roup were not countable due to high number of squamous cells
xpressed as median (range). Abbreviation - TCC: total cell count.
Figure 1 Graphical representation of difference in (a)
sputum eotaxin, MCP-1, IL-6 and MCP-4 and (b) sputum TNF-a
and IL-13 levels, in COPD non-producers and persistent sputum
producers. Boxes represent inter-quartile range and the hori-
zontal line is the median.
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ducers had increased concentrations of certain inflamma-
tory mediators also present in COPD sputum non-producers;
eotaxin, IL-6, MCP-1, and TNF-a levels in induced sputum
samples were increased. IL-6, MCP-1 and TNF-a are knownTable 4 Demographics of patients undergoing bacteriology.
Persistent spu
Age (Years) 66.0 (6.76)
Sex (M:F) 11/8
Smoking history (Pack years)* 39.2 (14e83)
Current smokers (n) 12/8
BMI (kg/m2) 26.4 (4.36)
GOLD I (n) 1
GOLD II (n) 12
GOLD III (n) 7
GOLD IV (n) 0
SABA (n) 19
SAMA (n) 3
LABA (n) 11
LAMA (n) 9
ICS (n) 11
Post bronchodilator FEV1 % predicted 59 (15.06)
Data presented as mean (standard deviation). * Data represented as m
short acting muscarinic antagonist; LABA: long acting b agonist; LAMAto upregulate mucin gene transcription [32e34], and may
therefore drive mucus hypersecretion. Eotaxin is an eosin-
ophil chemoattractant [35], and we also found increased
sputum eosinophil total cell numbers in persistent sputum
producers.
Previous studies have shown significantly higher levels of
some cytokines in the airways of subjects with chronic
bronchitis compared to healthy controls [18e20]. We have
now elucidated cytokines that are specifically associated
with the presence of chronic bronchitis in COPD patients, as
our control group comprised COPD patients without chronic
bronchitis. Persistent sputum producers had significantly
elevated levels of eotaxin, IL-6, MCP-1 and TNF-a compared
to non-producers, with a trend towards significance for
MCP-4 and IL-13. These inflammatory mediators all have
biological roles that may be of importance in COPD and
mucus hypersecretion; TNF-a is a potent neutrophil stimu-
lant [36], while IL-6, IL-13, MCP-1 and TNF-a all induce
mucin gene upregulation, [17,37]. Eotaxin and MCP-4 are
eosinophil chemo-attractants [35] that may play an
important role in causing increased eosinophil numbers in
induced sputum of persistent sputum producers.
It is known that a subgroup of COPD patients have
increased numbers of eosinophils in induced sputum [38].
Furthermore, a subset of patients with chronic bronchitis
also have increased eosinophil numbers in induced sputum
[39], and eosinophils are preferentially distributed towards
the airway lumen in COPD patients with chronic bronchitis
[21]. Eotaxin levels are increased in exacerbations of
chronic bronchitis [40]; our findings further support a po-
tential role for eosinophils in the pathophysiology of
chronic bronchitis. Eosinophils may contribute to mucus
hypersecretion through the action of TGF-a [41], or by
releasing mediators that stimulate degranulation of mucus-
producing cells [42].
There was evidence of increased neutrophil and eosin-
ophil cell counts on patients with more severe airflow
obstruction (GOLD stage III). This is compatible with the
increase in the number of inflammatory cells in the airwaystum producer (n Z 20) Non-persistent sputum
producer (n Z 13)
68.7 (4.70)
7/6
47.5 (21.50e119.18)
5/8
28.5 (4.04)
3
7
3
0
13
2
9
7
9
71.5 (8.85)
edian (range). Abbreviation - SABA: short acting b agonist; SAMA:
: long acting muscarinic antagonist; ICS: inhaled corticosteroid.
Table 5 Visit 1 (baseline) and Visit 2 (8 week) induced and spontaneous sputum cell counts.
Visit 1 (baseline) (n Z 12) Visit 2 (8 weeks) (n Z 12) p value Ri (p value)
Induced sputum indices
Total cell count, (106) 3.5 (3.11) 4.4 (2.82) 0.34 0.6 (0.008)*
Neutrophil % 73.4 (20.71) 76.1 (21.67) 0.32 0.6 (0.003)*
Macrophage % 11.7 (22.64) 13.3 (19.84) 0.68 0.6 (0.004)*
Eosinophil % 1.7 (0.54e2.94) 1.7 (0.59e2.98) 0.12 0.7 (0.001)*
Neutrophil cell count, (106) 2.1 (3.96) 2.3 (4.14) 0.54 0.8 (0.003)*
Macrophage cell count, (106) 0.3 (0.39) 0.4 (0.38) 0.25 0.7 (0.022)*
Eosinophil cell count, (106) 0.08 (0.05e0.12) 0.09 (0.07e0.15) 0.34 0.7 (0.026)*
Spontaneous sputum indices
Total cell count, (106) 3.3 (2.89) 2.5 (3.61) 0.56 0.4 (0.267)
Neutrophil % 68.7 (17.94) 78.4 (15.69) 0.60 0.1 (0.367)
Macrophage % 20 (14.44) 12.3 (12.97) 0.56 0.3 (0.146)
Eosinophil % 1.8 (0.61e2.92) 1.0 (0.45e1.79) 0.62 0.3 (0.513)
Neutrophil cell count, (106) 2.6 (3.77) 3.2 (3.21) 0.87 0.3 (0.156)
Macrophage cell count, (106) 0.3 (0.27) 0.5 (0.45) 0.38 0.3 (0.180)
Eosinophil cell count, (106) 0.06 (0.02e0.10) 0.01 (0.00e0.04) 0.32 0.1 (0.515)
Data represented as mean (SD). Eosinophil % and cell count expressed as median (range). Abbreviation - TCC: total cell count. * Shows
p value 0.05. Ri and p value denote intraclass correlation coefficient and its statistical significance.
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any of the supernatant proteins measured, which is perhaps
surprising given the difference for inflammatory cells. This
may be due to insufficient sample size of severe COPD pa-
tients (n Z 13) for this subanalysis.
Persistent sputum producers had higher total sputum
neutrophil and eosinophil counts, but there were no dif-
ferences in differential percentages between groups. This
suggests increased influx of both of these cell types into the
airways of persistent sputum producers, rather than se-
lective recruitment of one cell type. An increase in total
cell number, despite no change in percentage, is likely to
be of clinical relevance as it indicates an increase in the
overall burden of inflammatory cells within the airways.
Sputum neutrophil percentages in COPD show only very
weak correlations with clinical characteristics [29]. We
show that the neutrophil percentage is not changed in
COPD persistent sputum producers, but that these patients
display an increased overall total burden of neutrophils
(and eosinophils) in the airways.
Our results agree with previous data showing that
induced sputum has a higher number of viable cells and less
squamous cells compared to spontaneous sputum [43]. The
reduced viability of sputum samples can create practical
difficulties in cell identification and supernatant protein
measurements [44]. The reduced quality of spontaneous
samples was associated with worse reproducibility
compared to induced sputum. This has important implica-
tions for sequential sputum sampling, such as during clinical
trials, as more variable methods have less statistical power.
However, such variability can be reduced by using mean
values from samples collected on different days; this has
been shown to improve variability from spontaneous
sputum samples [45].
Mucus hypersecretion can cause plugging of the small
airways, predisposing to distal airway collapse and air
trapping. Persistent sputum producers had an increased
closing volume, possibly due to small airway mucusplugging, and a trend towards increased residual volume,
suggestive of hyperinflation. KCO, an indicator of emphy-
sema, was reduced in persistent sputum producers. It is
possible that persistent sputum producers had two causes
of hyperinflation; emphysema due to alveolar destruction,
and small airways mucus plugging. CT scanning to quantify
emphysema would have been a valuable tool to validate
this observation.
It has previously been reported that mucus hypersecre-
tion in COPD patients is associated with increased exacer-
bation rates [3,6e8], and we also observed this finding. This
may be due to increased colonization of pathogenic bac-
teria in patients with mucus hypersecretion as observed in
this study, or mucus impaction in the small airways leading
to worsening symptoms compatible with an exacerbation.
Prospective collection is the preferred method to evaluate
exacerbation rates; we used retrospective history, which is
known to be a good predictor of future exacerbation rates
[46].
COPD persistent sputum producers had evidence of more
severe clinical characteristics compared to non-sputum
producers, including reduced quality of life using the
SGRQ and CAT scores, worse airflow obstruction, reduced
exercise capacity and a worse prognostic BODE score. The
association between sputum production and both airflow
obstruction and SGRQ scores were confirmed by ordinal
regression. However, this analysis does not tell us whether
persistent sputum production is the cause of worse clinical
characteristics, or whether it arises as a consequence of
progression to severe disease. Furthermore, it is possible
that some of the effects of these markers of COPD severity
are mediated through exacerbations. However, it seems
plausible that persistent mucus hypersecretion per se af-
fects health status.
The proportion of persistent sputum producers with co-
existent bronchiectasis was low, and so was not associated
with persistent sputum production. Bronchiectasis rates in
COPD have varied greatly between studies with some
1768 S. Khurana et al.publications observing rates of 29e57% [47e49]. However,
the low rate reported here is compatible with observations
from the ECLIPSE study where 4% of COPD patients had
bronchiectasis [13]. This wide variation between studies is
difficult to explain, and may be due to differences in in-
clusion criteria for patient recruitment, geographical vari-
ation or methodology for assessment. Our sample size of
HRCT scans was limited, and hence we are not able to make
robust deductions about the associations between persis-
tent sputum production and the presence of bronchiectasis.
The study was powered on sputum cell counts, and the
sample size is similar to other induced sputum studies in
COPD patients investigating inflammatory cell counts and
cytokines [45,50,51]. The significant findings in sputum re-
ported here are biologically plausible or have strong sup-
port from the literature [32e35]. Further studies of the
function of the inflammatory mediators increased in
persistent sputum producers are warranted. The sample
size for assessing clinical characteristics was small, and it
would be of value for the sputum and clinical findings here
to be validated in a larger population. Our supernatant
protein findings could also be further validated by studies
using other techniques on sputum samples, such as gene
expression analysis [52].
We focused on measuring inflammation in induced
sputum samples. It would also have been informative to
measure mucins in the sputum samples, as cytokines are
known to increase mucin gene expression [33,37], which
could account for increased sputum production in patients
with chronic bronchitis.
In conclusion, persistent sputum production in COPD
patients is associated with different clinical characteristics
and increased concentrations of certain cytokines in
induced sputum. Increased levels of IL-6, MCP-1 and TNF-a
in the airways of persistent sputum producers may be a
cause of increased mucin gene expression, while increased
eotaxin may contribute to excessive eosinophilic inflam-
mation. Novel therapies that target these cytokines may
reduce the burden of mucus production and airway
inflammation in this COPD subgroup.
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